Menu
Search
|

Menu

Close
X

Clearside Biomedical Inc CLSD.OQ (NASDAQ Stock Exchange Global Market)

0.73 USD
-- (--)
As of Sep 18
Previous Close 0.73
Open --
Volume --
3m Avg Volume 161,189
Today’s High --
Today’s Low --
52 Week High 6.61
52 Week Low 0.56
Shares Outstanding (mil) 25.34
Market Capitalization (mil) 211.56
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.29 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
1
EPS (USD)
FY19
-0.603
FY18
-2.687
FY17
-2.329
FY16
-1.046
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
1,459.03
7.91
Price to Book (MRQ)
vs sector
3.89
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
14.35
14.55
LT Debt to Equity (MRQ)
vs sector
11.41
10.20
Return on Investment (TTM)
vs sector
-71.32
14.48
Return on Equity (TTM)
vs sector
-78.78
15.78

EXECUTIVE LEADERSHIP

Christy Shaffer
Chairman of the Board, Since 2012
Salary: --
Bonus: --
George Lasezkay
Interim Chief Executive Officer, Director, Since 2019
Salary: --
Bonus: --
Charles Deignan
Chief Financial Officer, Since 2012
Salary: $289,623.00
Bonus: --
Leslie Zacks
Chief Compliance Officer, General Counsel, Since 2018
Salary: --
Bonus: --
Thomas Crawford
Vice President - Supply Chain, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

900 N Point Pkwy Ste 200
ALPHARETTA   GA   30005-8995

Phone: +1678.2703631

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting three components of the eye: the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision; the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment, and the sclera, which is the outer protective layer of the eye. The Company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide formulated for administration via suprachoroidal injection.

SPONSORED STORIES